Landos Biopharma, Inc. Stock News

Landos Biopharma (NASDAQ:LABP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “Landos Biopharma Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. Landos Biopharma Inc. […]

Zacks Investment Research upgraded shares of Landos Biopharma (NASDAQ:LABP) from a hold rating to a buy rating in a research report sent to investors on Thursday morning, Zacks.com reports. The firm currently has $11.00 price objective on the stock. According to Zacks, “Landos Biopharma Inc. is a clinical-stage biopharmaceutical company. It is focused on the […]

Jonestrading downgraded shares of Landos Biopharma (NASDAQ:LABP) from a buy rating to a hold rating in a report published on Monday, The Fly reports. Several other research analysts have also recently issued reports on LABP. SVB Leerink reiterated a buy rating on shares of Landos Biopharma in a report on Thursday, October 7th. Zacks Investment []

Landos Biopharma, Inc. (NASDAQ:LABP) Analysts at Jefferies Financial Group increased their FY2021 EPS estimates for Landos Biopharma in a research note issued to investors on Monday, November 15th. Jefferies Financial Group analyst C. Howerton now expects that the company will post earnings of ($0.88) per share for the year, up from their previous forecast []

Landos Biopharma (NASDAQ:LABP) was downgraded by research analysts at SVB Leerink from an outperform rating to a market perform rating in a research note issued to investors on Tuesday, Price Targets.com reports. They presently have a $16.00 price target on the stock, down from their previous price target of $20.00. SVB Leerinks price objective would []

Landos Biopharma (NASDAQ:LABP) released its quarterly earnings results on Monday. The company reported ($0.32) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.44) by $0.12, MarketWatch Earnings reports. Shares of LABP stock traded down $2.67 during trading hours on Tuesday, hitting $11.34. 9,320 shares of the company were exchanged, compared to its []

Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization

Landos Biopharma, Inc.'s (LABP) CEO Tim Mayleben on Q3 2021 Results - Earnings Call Transcript

Landos Biopharma (LABP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Phase 1 trial initiation expected before yearend with topline results in 1H 2022

BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and d

BLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel

BLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel